Inhaled salbutamol induces leanness in well-trained healthy females but not males during a period of endurance training: a randomised controlled trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Inhaled salbutamol induces leanness in well-trained healthy females but not males during a period of endurance training : a randomised controlled trial. / Hostrup, Morten; Weinreich, Cecilie; Bjerre, Mathias; Kohlbrenner, Dario; Bangsbo, Jens; Jessen, Søren.

I: ERJ Open Research, Bind 9, Nr. 6, 00657-2023, 2023.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Hostrup, M, Weinreich, C, Bjerre, M, Kohlbrenner, D, Bangsbo, J & Jessen, S 2023, 'Inhaled salbutamol induces leanness in well-trained healthy females but not males during a period of endurance training: a randomised controlled trial', ERJ Open Research, bind 9, nr. 6, 00657-2023. https://doi.org/10.1183/23120541.00657-2023

APA

Hostrup, M., Weinreich, C., Bjerre, M., Kohlbrenner, D., Bangsbo, J., & Jessen, S. (2023). Inhaled salbutamol induces leanness in well-trained healthy females but not males during a period of endurance training: a randomised controlled trial. ERJ Open Research, 9(6), [00657-2023]. https://doi.org/10.1183/23120541.00657-2023

Vancouver

Hostrup M, Weinreich C, Bjerre M, Kohlbrenner D, Bangsbo J, Jessen S. Inhaled salbutamol induces leanness in well-trained healthy females but not males during a period of endurance training: a randomised controlled trial. ERJ Open Research. 2023;9(6). 00657-2023. https://doi.org/10.1183/23120541.00657-2023

Author

Hostrup, Morten ; Weinreich, Cecilie ; Bjerre, Mathias ; Kohlbrenner, Dario ; Bangsbo, Jens ; Jessen, Søren. / Inhaled salbutamol induces leanness in well-trained healthy females but not males during a period of endurance training : a randomised controlled trial. I: ERJ Open Research. 2023 ; Bind 9, Nr. 6.

Bibtex

@article{524ee80f98bd4c6d8f68007eaf118b31,
title = "Inhaled salbutamol induces leanness in well-trained healthy females but not males during a period of endurance training: a randomised controlled trial",
abstract = "Introduction Many athletes use short-acting inhaled β2-agonists multiple times weekly during training sessions to prevent exercise-induced bronchoconstriction, but it is unclear if treatment impairs training outcomes. Herein, we investigated performance adaptations in well-trained females and males training with prior inhalation of salbutamol. Methods 19 females and 21 males with maximal oxygen uptake (V′O2max) of 50.5±3.3 and 57.9±4.9 mL·min−1·kg−1, respectively, participated in this double-blinded, placebo-controlled, parallel-group study. We randomised participants to placebo or salbutamol inhalation (800–1600 µg·training day−1) for 6 weeks of combined endurance (1× per week) and high-intensity interval training (2× per week). We assessed participants{\textquoteright} body composition, V′O2max and muscle contractile function, and collected vastus lateralis muscle biopsies. Results Salbutamol induced a sex-specific loss of whole-body fat mass (sex×treatment: p=0.048) where only salbutamol-treated females had a fat mass reduction compared to placebo (–0.8 kg at 6 weeks; 95% CI: −0.5 to −1.6; p=0.039). Furthermore, salbutamol-treated females exhibited a repartitioning effect, lowering fat mass while gaining lean mass (p=0.011), which was not apparent for males (p=0.303). Salbutamol negatively impacted V′O2max in both sexes (treatment main effect: p=0.014) due to a blunted increase in V′O2max during the initial 4 weeks of the intervention. Quadriceps contractile strength was impaired in salbutamol-treated females (−39 N·m; 95% CI: −61 to −17; p=0.002) compared to placebo at 6 weeks. Muscle electron transport chain complex I–V abundance increased with salbutamol (treatment main effect: p=0.035), while content of SERCAI, β2-adrenoceptor and desmin remained unchanged. Conclusion Inhaled salbutamol appears to be an effective repartitioning agent in females but may impair aerobic and strength-related training outcomes.",
author = "Morten Hostrup and Cecilie Weinreich and Mathias Bjerre and Dario Kohlbrenner and Jens Bangsbo and S{\o}ren Jessen",
note = "Publisher Copyright: {\textcopyright} The authors 2023.",
year = "2023",
doi = "10.1183/23120541.00657-2023",
language = "English",
volume = "9",
journal = "ERJ Open Research",
issn = "2312-0541",
publisher = "ERS publications",
number = "6",

}

RIS

TY - JOUR

T1 - Inhaled salbutamol induces leanness in well-trained healthy females but not males during a period of endurance training

T2 - a randomised controlled trial

AU - Hostrup, Morten

AU - Weinreich, Cecilie

AU - Bjerre, Mathias

AU - Kohlbrenner, Dario

AU - Bangsbo, Jens

AU - Jessen, Søren

N1 - Publisher Copyright: © The authors 2023.

PY - 2023

Y1 - 2023

N2 - Introduction Many athletes use short-acting inhaled β2-agonists multiple times weekly during training sessions to prevent exercise-induced bronchoconstriction, but it is unclear if treatment impairs training outcomes. Herein, we investigated performance adaptations in well-trained females and males training with prior inhalation of salbutamol. Methods 19 females and 21 males with maximal oxygen uptake (V′O2max) of 50.5±3.3 and 57.9±4.9 mL·min−1·kg−1, respectively, participated in this double-blinded, placebo-controlled, parallel-group study. We randomised participants to placebo or salbutamol inhalation (800–1600 µg·training day−1) for 6 weeks of combined endurance (1× per week) and high-intensity interval training (2× per week). We assessed participants’ body composition, V′O2max and muscle contractile function, and collected vastus lateralis muscle biopsies. Results Salbutamol induced a sex-specific loss of whole-body fat mass (sex×treatment: p=0.048) where only salbutamol-treated females had a fat mass reduction compared to placebo (–0.8 kg at 6 weeks; 95% CI: −0.5 to −1.6; p=0.039). Furthermore, salbutamol-treated females exhibited a repartitioning effect, lowering fat mass while gaining lean mass (p=0.011), which was not apparent for males (p=0.303). Salbutamol negatively impacted V′O2max in both sexes (treatment main effect: p=0.014) due to a blunted increase in V′O2max during the initial 4 weeks of the intervention. Quadriceps contractile strength was impaired in salbutamol-treated females (−39 N·m; 95% CI: −61 to −17; p=0.002) compared to placebo at 6 weeks. Muscle electron transport chain complex I–V abundance increased with salbutamol (treatment main effect: p=0.035), while content of SERCAI, β2-adrenoceptor and desmin remained unchanged. Conclusion Inhaled salbutamol appears to be an effective repartitioning agent in females but may impair aerobic and strength-related training outcomes.

AB - Introduction Many athletes use short-acting inhaled β2-agonists multiple times weekly during training sessions to prevent exercise-induced bronchoconstriction, but it is unclear if treatment impairs training outcomes. Herein, we investigated performance adaptations in well-trained females and males training with prior inhalation of salbutamol. Methods 19 females and 21 males with maximal oxygen uptake (V′O2max) of 50.5±3.3 and 57.9±4.9 mL·min−1·kg−1, respectively, participated in this double-blinded, placebo-controlled, parallel-group study. We randomised participants to placebo or salbutamol inhalation (800–1600 µg·training day−1) for 6 weeks of combined endurance (1× per week) and high-intensity interval training (2× per week). We assessed participants’ body composition, V′O2max and muscle contractile function, and collected vastus lateralis muscle biopsies. Results Salbutamol induced a sex-specific loss of whole-body fat mass (sex×treatment: p=0.048) where only salbutamol-treated females had a fat mass reduction compared to placebo (–0.8 kg at 6 weeks; 95% CI: −0.5 to −1.6; p=0.039). Furthermore, salbutamol-treated females exhibited a repartitioning effect, lowering fat mass while gaining lean mass (p=0.011), which was not apparent for males (p=0.303). Salbutamol negatively impacted V′O2max in both sexes (treatment main effect: p=0.014) due to a blunted increase in V′O2max during the initial 4 weeks of the intervention. Quadriceps contractile strength was impaired in salbutamol-treated females (−39 N·m; 95% CI: −61 to −17; p=0.002) compared to placebo at 6 weeks. Muscle electron transport chain complex I–V abundance increased with salbutamol (treatment main effect: p=0.035), while content of SERCAI, β2-adrenoceptor and desmin remained unchanged. Conclusion Inhaled salbutamol appears to be an effective repartitioning agent in females but may impair aerobic and strength-related training outcomes.

U2 - 10.1183/23120541.00657-2023

DO - 10.1183/23120541.00657-2023

M3 - Journal article

C2 - 38152086

AN - SCOPUS:85180885479

VL - 9

JO - ERJ Open Research

JF - ERJ Open Research

SN - 2312-0541

IS - 6

M1 - 00657-2023

ER -

ID: 390411243